Last reviewed · How we verify
NCT02843204
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
Completed
Phase 1, PHASE2
Last updated 28 May 2020
What this trial tests
Phase 1, PHASE2 trial testing Pembrolizumab in Malignant Solid Tumour in 110 participants. Completed in 1 July 2019.
Timeline
1 July 2016
Primary endpoint
1 July 2017
1 July 2017
1 July 2019
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 110 |
| Start date | 1 July 2016 |
| Primary completion | 1 July 2017 |
| Estimated completion | 1 July 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Pembrolizumab (pembrolizumab) — full drug profile →
- NK immunotherapy — full drug profile →
Conditions studied
- Malignant Solid Tumour — all drugs for Malignant Solid Tumour →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Adults 18 to 70, any sex, with Malignant Solid Tumour. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is the safety and efficacy of anti-PD-1 plus NK immunotherapy to multiple solid tumors.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Exploring treatment options in cancer: Tumor treatment strategies.
Liu B, Zhou H, Tan L, Siu KTH, et al · · 2024 · cited 536× · PMID 39013849 · DOI 10.1038/s41392-024-01856-7 -
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O, Lucarini V, Cifaldi L, Fruci D. · · 2019 · cited 324× · PMID 32038612 · DOI 10.3389/fimmu.2019.03038 -
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C, Dellepiane C, Carrega P, Sommariva S, et al · · 2021 · cited 168× · PMID 35069581 · DOI 10.3389/fimmu.2021.799455 -
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N, Panella D, Georgoudaki AM, Liu H, et al · · 2022 · cited 125× · PMID 36348457 · DOI 10.1186/s13045-022-01382-5 -
Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.
Lin M, Luo H, Liang S, Chen J, et al · · 2020 · cited 117× · PMID 32027620 · DOI 10.1172/jci132712 -
NK Cells in Cancer: Mechanisms of Dysfunction and Therapeutic Potential.
Portale F, Di Mitri D. · · 2023 · cited 61× · PMID 37298470 · DOI 10.3390/ijms24119521 -
Trial Watch: Adoptively transferred cells for anticancer immunotherapy.
Fournier C, Martin F, Zitvogel L, Kroemer G, et al · · 2017 · cited 55× · PMID 29147628 · DOI 10.1080/2162402x.2017.1363139 -
New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.
Corraliza-Gorjón I, Somovilla-Crespo B, Santamaria S, Garcia-Sanz JA, et al · · 2017 · cited 49× · PMID 29312320 · DOI 10.3389/fimmu.2017.01804
Verify or expand the search:
- PubMed search for NCT02843204
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pembrolizumab
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
Other recruiting trials for Malignant Solid Tumour
Currently open trials in the same condition.
- NCT07044336 — Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) · Phase 3 · recruiting
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02843204 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 28 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02843204.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing